Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC006 in Advanced Solid Tumors and GCTTS
NCT05212896Phase 1Unknown
- Sponsor
- Dragonboat Biopharmaceutical
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BC-006 in solid tumor (advanced stage) and giant cell tumor of tendon sheath (GCTTS) (3 arms), sponsored by Dragonboat Biopharmaceutical. Primary endpoints: Number of Participants Experiencing Dose-limiting Toxicities up to 28 days, Maximum Tolerated Dose of BC006 up to 28 days and 3 more. Status: unknown.
02
Drugs
BC-006
03
Conditions
solid tumor (advanced stage)giant cell tumor of tendon sheath (GCTTS)
Beyond the preview
Go deeper on NCT05212896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212896.